GI Innovation CEO On Developing World’s First Microbiome-Biologics Combo
Executive Summary
With an ultimate goal to develop the world’s first microbiome and protein drug combination therapies using its platform technology, GI Innovation is rapidly progressing its protein drug pipeline in allergic diseases and cancer on the back of its expert teams and external partnerships, the South Korean bioventure’s CEO tells Scrip.
You may also be interested in...
Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021
Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.
Microbiome Clinical Studies Loom Large In 2018
Events are moving fast in the microbiome field. The sector is expecting results from numerous initial clinical studies during 2018, from across a spectrum of approaches and mechanisms of action, which could lead to new rounds of financings and M&A activity.
Korea’s First Home-Grown COVID-19 Vaccine To Speed Hub Ambitions
Only one last step remains before the approval of South Korea’s first home-grown COVID-19 vaccine as SK Bioscience’s SKYCovione (GBP510) receives positive assessments from review committees. Any nod, which could happen this week, would mark a milestone for the country's ambitions of becoming a global vaccine hub.